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Letter to the Editor for “Auto-injector needle length may be inadequate to deliver epinephrine intramuscularly in
women with confirmed food allergy” by Tsai et al. There are limitations of this study note mentioning such as method
of compression, role of propulsion, defining those patients who are at risk of prophylaxis and future studies.
Keywords: Anaphylaxis, Epinephrine, Auto-injector, Needle lengthTo the Editor
I read with interest the article “Auto-injector needle
length may be inadequate to deliver epinephrine intra-
muscularly in women with confirmed food allergy” by
Tsai et al. [1]. The authors report findings from a study
assessing adequacy of epinephrine needle length by
measuring muscle depth at the recommended site of
injection for adult males and females. There are some
limitations in the study worth noting.
Tsai et al. noted that this is the first study to exam
needle length delivery in patients who are “at risk for
anaphylaxis”. This is in alignment with the European
Academy of Allergy, Asthma and Clinical Immunology
(EAACI) public declaration on food allergy and anaphyl-
axis in that they recommend that all patients at risk for
anaphylaxis should carry epinephrine auto-injector [2].
EAACI recommend that epinephrine auto-injectors be
available in public places since there are patients who
may have first episode of anaphylaxis and do not have
epinephrine auto-injectors available to them. However,
do patients at risk for anaphylaxis have different weight,
height or BMI, body mass index, profile than those with-
out risk for anaphylaxis? I am not aware of any current
published literature that answers this question. Until
that has been studied, physicians have to recommendCorrespondence: Tsong@allergyasthmass.com
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with varying BMI’s and not to those only at risk of
anaphylaxis.
I applaud Tsai et al. for considering compression in
their study, which is one of the factors that play a role in
ensuring delivery of epinephrine to the intramuscular
space. In their study, one physician applied an ultrasound
probe with maximum pressure as defined as “pressure
mimicking that required for proper auto-injection”. The
mean change in skin-to-muscle depth (STMD) with pres-
sure was 11% for all subjects and 16% for women. In a
pilot study that we published in 2005, there was 19% re-
duction in STMD in males and 25% in females [3]. In our
study, we placed an 8 lb weight block on top of the
EpiPen® auto-injector trainer to simulate the compres-
sion in a patient who was laying lateral recumbent. I agree
with Tsai et al. that the surface area of the auto-injector is
different from the ultrasound transducer. Yet, I believe
that the smaller surface area of EpiPen® compared to ultra-
sound transducer tip has a significant role in human studies.
The small surface area can increase compression of the
subcutaneous tissue to deliver epinephrine beyond the
length of the needle-length. The difference in STMD with
pressure in the two studies is most likely due to surface
area of EpiPen® (Song et al.) versus ultrasound transducer
(Tsai et al.). The other factors that are not addressed in
this study that effect the delivery of epinephrine into theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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injection, and bore diameter.
Another factor that is crucial to proper delivery of epi-
nephrine is the propulsion of the auto-injector. Almost all
the epinephrine auto-injectors are spring loaded. In other
words, there is a spring that is tightly coiled and has pro-
pulsion force. We published an in vivo study in pig thighs
which shows that the STMD was 2.78 ± 0.59 cm (range, 2–
4 cm) with p = <0.0001 (one sample t-test) [4]. The STMD
delivery of epinephrine was 94.4% beyond the length of the
auto-injector needle. The authors believe that compression,
or hand swing, and propulsion by the spring loaded auto-
injector, have a role in delivery of epinephrine beyond the
needle length. In the United Kingdom, there is an epine-Authors’ response
Harold Kim, Sten Dreborg, Laura Kim, Gina Tsaiphrine auto-injector, Emerade®, which has a needle length
of 2.5 cm. Tsai et al. believe that at this needle length, 96%
of their female patients would receive epinephrine intra-
muscularly. I agree that the needle length of 2.5 cm would
be helpful in many female patients with high BMI but it
may be too long for some males with normal to overweight
BMI. Further in vivo studies considering compression of
tissue and propulsion, dispersion of epinephrine beyond
needle tip, and the ideal needle length would be helpful.
In addition, future studies in human models, stratify-
ing patients based on BMI would be helpful. I look
forward to a table with gender, BMI and STMD so that
we can recommend a proper needle length for our
patients who are at risk of anaphylaxis.The authors’ reply: Song raises a number of important
questions regarding some potential limitations of our
study "Auto-injector needle length may be inadequate to
deliver epinephrine intramuscularly in women with con-
firmed food allergy”. (1) We will address each issue.
The first concern is whether patients at risk for ana-
phylaxis have different weight, height or BMI then pa-
tients who are not at risk for anaphylaxis. As far as we
are aware, Song’s comments are correct in that there is
no data comparing these variables in adults with and
without food allergy. In our study, we felt that it seemed
most logical to study the population at risk of anaphyl-
axis. The mean BMI for all subjects in our study was 25
kg/m2. (1) Data from a general census in the same mu-
nicipality where the study was completed showed that
53.9% of adults were either overweight or obese in 2011-
2012. Unfortunately, the mean BMI was not reported in
the census.(2) So we are uncertain of the differences of
the BMI of our subjects with food allergy and the gen-
eral population. As well, the range of BMI in our study
was quite wide at 18 to 50 kg/m2 and although the BMI
correlated with STMD it was not a perfect predictor of
adequate STMD for the epinephrine auto-injectors. We
concluded in our paper that patients at risk of anaphyl-
axis and especially women should have an ultrasound of
the mid-anterior thigh completed to determine if the
STMD is adequate for an epinephrine auto-injector.
In our study, we attempted to simulate the STMD dis-
tance when an epinephrine auto-injector is delivered by
performing our ultrasound measurements with "max-
imal" pressure in the mid anterolateral thigh. Certainly,
this technique is not perfect. Optimally, an ultrasound
probe with the exact surface area of each epinephrine
auto-injector pushed down at the exact pressure used totrigger the auto-injector should be used to measure the
STMD. But as noted in our paper, even if we applied the
exact pressure that is required to trigger the auto-injec-
tors, it will not be an indicator of the exact pressure
used when the auto-injector is used in real life. So we
used "maximum” pressure at the appropriate site for epi-
nephrine injection. We felt that with this technique we
would be estimating the STMD that would be attained
with the auto-injectors in the “best case scenario” for
adults. Song references his paper showing a 19% reduc-
tion in STMD in males and a 25% reduction in females
using an 8 pound weight for compression. (3) These
measurements were completed on one male and one fe-
male only. We do not believe that this is the best ap-
proach to estimate compression in all subjects. In fact,
in our paper the percent change in STMD with and
without "maximal" pressure or compression ranged from
0 to 45% with a mean of 11%. Again, we would recom-
mend performing ultrasound measurements in all sub-
jects at risk of anaphylaxis with and without pressure.
As well, future studies are required to assess tissue com-
pression with more accurate models simulating epineph-
rine auto-injector use. A third concern raised by Song is
that the STMD may underestimate the true delivery
depth of the epinephrine. He points out that the epi-
nephrine would be delivered deeper than the tip of the
needle because the auto-injectors are spring-loaded lead-
ing to a propulsion force and deeper delivery of the
medication. In his study, using pig thighs, it was shown
that the delivery of epinephrine was 94.4% deeper than
the needle tip. (4) This data is interesting and may be
true for the injection within one tissue compartment.
But a study presented this year at the European allergy
meeting showed that the epinephrine delivery would stay
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subcutaneous space. More specifically, the needle tip
would have to penetrate the muscle fascia to deliver the
epinephrine intramuscularly. (5) Therefore, we stand by
our suggestion that we require longer needle lengths for
some subjects where the STMD is greater than the
needle lengths of the currently available auto-injectors.
As well, Song raised a concern that a 2.5 cm needle
length may be too long for some male subjects. We
agree that this is a may be a possibility in very few
subjects with thin thighs. Epinephrine auto-injectors
with the appropriate needle length that require a lower
pressure for injection may be required in these subjects.
In summary, we agree that future research correlating
variables such as gender, BMI and STMD would be
helpful in subjects at risk of anaphylaxis. But we believe
that a “personalized” medicine approach with the use of
ultrasound and then recommending the auto-injectors
with the appropriate needle length and dose of epine-
phrine is the best clinical approach. Finally, patients at
risk of anaphylaxis should have two auto-injectors avail-
able and they should seek medical attention immediately
if a auto-injector(s) is required.
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